Company Overview of Sanofi US Services Inc.
Sanofi US Services Inc. develops, manufactures, and distributes pharmaceutical products in the United States. Its products include prescription medicines, vaccines, and other products. The company develops products in therapeutic areas including cardiovascular disease, central nervous system, internal medicine, metabolic disorders, oncology, ophthalmology, and thrombosis. It also offers biopolymer gels that allow surgeons to temporarily stop blood flow during surgery. Sanofi US Services Inc. was formerly known as Sanofi-Aventis U.S. Inc. The company was founded in 1950 and is based in Bridgewater, New Jersey. It operates pharmaceutical research sites in Bridgewater, New Jersey; Malvern, Penn...
55 Corporate Drive
Bridgewater, NJ 08807
Founded in 1950
Key Executives for Sanofi US Services Inc.
Chief Executive Officer of Genzyme and President of Genzyme
President of Merial North America
Head of Global Supply Chain and Vice President of Global Supply Chain
Head of the North America R&D Hub and Vice President of Disposition, Safety, and Animal Research Scientific Core Platform
Senior Vice President of Global Services
Compensation as of Fiscal Year 2015.
Sanofi US Services Inc. Key Developments
Sanofi US Announces Results from Real World Outcome Study of Type 2 Diabetes
Jun 14 14
Sanofi US announced results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus(R) (insulin glargine [rDNA origin] injection) to insulin detemir demonstrated higher average blood sugar levels (A1C) and lower A1C reduction over a span of 12 months compared to maintaining patients on Lantus. Alternatively, switching patients from insulin detemir to Lantus resulted in a significantly lower A1C compared to maintaining patients on insulin detemir. The study findings were presented at the 74(th) Scientific Sessions of the American Diabetes Association in San Francisco, Calif. This was a retrospective study (using an electronic medical records database) of two cohorts of adult T2D patients who had hemoglobin A1C (A1C) and weight measures at baseline that were examined between 2006 and 2012. Overall, 13,942 patients were included (female 54%, mean baseline age 58 year, average A1C 8.7%). Cohort 1 was switched to insulin detemir (DET-S) from insulin glargine or continued on insulin glargine (GLA-C) and Cohort 2 was switched to insulin glargine (GLA-S) from insulin detemir or continued on insulin detemir (DET-S). At one year follow up, in Cohort 1, compared with GLA-C patients, DET-S patients were significantly less persistent with treatment (52.5% vs 61.4%; P < 0.0001), had a significantly higher A1C (8.5% vs. 8.2%, P < 0.0001), experienced significantly less A1C reduction (-0.24% vs. -0.46%, P<0.0001) and a significantly lower proportion of patients achieved A1C <7% (21.0% vs. 26.1%, P<0.0001) and A1C <8% (45.7% vs. 53.2%, P<0.0001) despite a significantly higher proportion of DET-S patients using rapid acting insulin (57.7% vs. 52.5%, P<0.0001); there were no significant differences in hypoglycemia rate (DET-S: 2.1% vs. GLA-C: 2.1%, P=0.8894) or weight gain (DET-S: -0.35 lbs. vs. GLA-C: 0.21 lbs., P=0.3480) between the groups. In contrast, at one year follow up, in Cohort 2, compared with DET-C patients, GLA-S patients had a significantly lower A1C (GLA-S: 8.1% vs. DET-C: 8.3%, P=0.0213) and a similar A1C reduction (GLA-S: -0.6% vs. DET-C: -0.5%, P=0.0703); the proportions of patients achieving A1C <7% (GLA-S: 25.1% vs. DET-C: 23.6%, P=0.3929), A1C <8% (GLA-S: 54.8% vs. DET-C: 51.3%, P=0.0794), and hypoglycemia rates (GLA-S: 2.3% vs. DET-C: 1.7%, P=0.2314) were similar between groups; GLA-S patients had significantly greater weight gain than DET-C (GLA-S: 3.2 lbs. vs. DET-C: 0.07 lbs., P<0.001). Clinical data also needs to be considered when making treatment decisions as there are some limitations to real world outcomes data.
Sanofi US Services Inc. Presents at Latin America & Caribbean Life Sciences Conference, Mar-27-2014 04:35 PM
Mar 24 14
Sanofi US Services Inc. Presents at Latin America & Caribbean Life Sciences Conference, Mar-27-2014 04:35 PM. Venue: Graham Center Ballroom, FIU-Maidique Campus, Miami, Florida, United States. Speakers: Ana Radeljevic, Director of Biosurgery Business Planning.
Sanofi US Services Inc. Presents at Life Sciences Summit 2013, Nov-21-2013 01:15 PM
Nov 2 13
Sanofi US Services Inc. Presents at Life Sciences Summit 2013, Nov-21-2013 01:15 PM. Venue: Convene - Midtown East, 730 Third Avenue (Between East 45th and 46th Streets), 17th Floor, New York, NY 10017, United States. Speakers: Kenneth I Maynard, FAHA, Global Head, External Innovation, Aging, Therapeutic Strategic Unit.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|